Keros Therapeutics (KROS) Stock: Buy, Sell, or Hold?
KROS - Keros Therapeutics, Inc. Common Stock
$11.36
0.10 (0.89%)
▲
5d:
-2.24%
30d:
+1.16%
90d:
+2.99%
HOLD
MODERATE Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 04, 2026
Get Alerted When KROS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: KROS shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: KROS shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: KROS is currently trading at $11.36, which is considered fair relative to its 30-day fair value range of $11.03 to $11.49.
Technical Outlook: Technically, KROS is in a uptrend. Immediate support is located at $10.93, while resistance sits at $12.05.
Market Sentiment: The stock scores a mixed 44/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $19.83 (+74.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, KROS is in a uptrend. Immediate support is located at $10.93, while resistance sits at $12.05.
Market Sentiment: The stock scores a mixed 44/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $19.83 (+74.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$11.03 -
$11.49
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
80.0%
Protect Your Profits
Holding KROS? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (44/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 74.6% below Wall St target ($19.83)
- NEUTRAL: Bottoming setup forming (44/100) — watch for confirmation
Trading Range Analysis
30-Day Trading Range
$11.03 -
$11.49
Current vs Trading Range
FAIR
Expected Move (7 Days)
±$0.79
(7.0%)
Support & Resistance Levels
Support Level
$10.93
Resistance Level
$12.05
Current Trend
Uptrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.72
Wall Street Target
$19.83
(+74.6%)
Revenue Growth (YoY)
-99.8%
Share & Embed Analysis
Last updated: October 02, 2026 9:46 PM ET
Data refreshes hourly during market hours. Next update: 10:46 PM
Data refreshes hourly during market hours. Next update: 10:46 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is KROS showing a specific setup today?
Insider Activity (6 Months)
1
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Jean Jacques Bienaime
BUY
1000 shares
2026-04-15
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$92 | 46 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 65 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$109 | 76 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 42 HOLD |
|
SRRK
Scholar Rock Holding Corp |
STRONG BUY
10 analysts |
$70 | 68 BUY |
Advanced KROS Option Strategies
Professional options setups generated by AI based on today's KROS price and gamma walls.
